Thermo Fisher Sells Unit for $1.08B

Thermo Fisher Scientific (TMO) has entered into an agreement to divest its microbiology business to private equity firm Astorg in a $1.08 billion transaction, as the life sciences leader reshapes its diagnostics portfolio.

This strategic divestiture reflects Thermo Fisher’s initiative to eliminate slower-growth assets while confronting reduced post-pandemic demand pressures and concentrating capital on higher-margin business segments.

Key Takeaways

Thermo Fisher divesting microbiology unit for $1.08 billion cash
Astorg acquiring business that makes infectious disease testing equipment
Move follows broader industry trend of portfolio optimization

Market reaction & context

This transaction emerges as life sciences enterprises reevaluate their business portfolios in the wake of the pandemic surge. Thermo Fisher’s diagnostics operations have encountered challenges as COVID-19 testing requirements returned to normal levels, creating pressure for the company to refine its asset composition ¹.

The microbiology division produces approximately $300 million in adjusted earnings each year from $1.4 billion in revenue, accounting for roughly one-third of Thermo Fisher’s comprehensive specialty diagnostics operation. The transaction assigns a valuation of approximately 3.6 times revenue to the unit, consistent with recent diagnostics sector deals ².

Strategic rationale

This transaction demonstrates Thermo Fisher’s methodical approach to capital deployment as the organization aims to exit peripheral business units. Earlier this year, industry reports indicated the company was considering divesting portions of its diagnostics division valued at roughly $4 billion ³.

Astorg’s purchase corresponds with private equity’s increasing focus on healthcare investments offering reliable cash generation. The Paris-headquartered firm has established a track record investing in medical technology and pharmaceutical services enterprises throughout Europe ⁴.

Industry consolidation continues

This agreement marks another milestone in ongoing diagnostic sector consolidation as organizations streamline their operations. Competitor Becton Dickinson recently revealed intentions to spin off its life sciences division, encompassing diagnostics operations, demonstrating comparable strategic objectives ⁵.

Concurrently, Thermo Fisher maintains its expansion into faster-growing markets through strategic acquisitions, recently completing an $8.9 billion transaction to purchase clinical trial data company Clario from a group led by Astorg and Nordic Capital ⁶.

Financial implications

The microbiology divestiture consists of $1.08 billion in cash proceeds plus a $50 million seller note. Thermo Fisher anticipates deploying the proceeds toward growth investments and debt reduction following substantial recent acquisitions.

The deal is anticipated to conclude by mid-2026, pending regulatory clearances and standard closing requirements. Following completion, the divested operation will function independently under Astorg’s management.

Outlook

This divestiture enables Thermo Fisher to concentrate resources on its primary laboratory products and biopharma services operations, which present superior growth opportunities. The organization has shown reliable performance in executing its portfolio optimization approach throughout recent years.

For Astorg, this acquisition delivers access to the resilient diagnostics marketplace while creating opportunities for operational enhancements and geographic expansion through private equity stewardship.

Not investment advice. For informational purposes only.